Shots: The P-III EMPEROR Trial involves assessing of Jardiance (10 mg) vs PBO in two studies EMPEROR-Reduced [NCT03057977, N=3,730] & EMPEROR-Preserved [NCT03057951, N=5,990] in patients with HFrEF & HFpEF respectively The EMPEROR-Reduced study meets its 1EPs in reducing the risk for the composite of cardiovascular death or hospitalization due to heart failure while the overall […]Read More
Shots: Abbott has recalled 13,891 NC Trek RX and NC Traveler RX coronary dilatation catheter with 4.0mm, 4.5mm and 5.0mm balloon diameters, distributed b/w Aug’2019 to Jan’2020 in the US. The FDA has labeled it as Class I recall The recall is due to the inability of balloons to deflate as intended. The problem stems […]Read More
Shots: Smith Medical has recalled its Medfusion 4000 syringe pump with firmware version 1.7.0 due to malfunctioning alarms and potential interruption of therapy. The FDA has labeled it as Class I recall The 627 devices have recalled having model numbers are 4000-0107-01 and 4000-0106-01, manufactured on Jun 25, 2019, and distributed b/w Sept 27, 2019, […]Read More
Shots: Teva was assessing laquinimod since 2007, globally the drug completed three P-III studies ALLEGRO, BRAVO and CONCERTO in rrMS, P-II study ARPEGGIO in primary progressive MS and single P-II LEGATO-HD trial in Huntington’s Disease(HD) The P-II LEGATO-HD trial in HD fails to meet 1EP@12 mos, additionally in Dec 2017, P-II POC study of laquinimod […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
